US FDA grants priority review status to Allergan ’s sNDA for Avycaz
The US Food and Drug Administration (FDA) has granted priority review status for Allergan ’s supplemental New Drug Application (sNDA) for Avycaz (ceftazidime and avibactam) to treat hospital-acquired bacterial pneumonia / ventilator-associated bacteri…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Allergy | Bacterial Pneumonia | Food and Drug Administration (FDA) | Grants | Hospitals | New Drug Applications | Pharmaceuticals | Pneumonia